Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.9610
+0.00190.20%
Pre-market: 0.96100.00000.00%04:08 EDT
Volume:251.05K
Turnover:237.38K
Market Cap:13.45M
PE:-0.09
High:0.9699
Open:0.9100
Low:0.9100
Close:0.9591
Loading ...

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

TipRanks
·
Yesterday

BRIEF-Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial

Reuters
·
01 Apr

Moleculin Biotech Inc - Preliminary Data From First 45 Subjects Expected in H2 2025

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 Miracle Trial

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

GlobeNewswire
·
01 Apr

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Zacks
·
27 Mar

Moleculin Biotech Raised to Buy From Hold by Maxim Group

Dow Jones
·
25 Mar

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4

MT Newswires Live
·
25 Mar

Moleculin Biotech Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
25 Mar

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com
·
25 Mar

Q4 2024 Moleculin Biotech Inc Earnings Call

Thomson Reuters StreetEvents
·
25 Mar

Moleculin Biotech Advances Clinical Trials Amid Financial Losses

TIPRANKS
·
25 Mar

Moleculin Biotech Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Moleculin Biotech Shares Corporate Presentation Update

TIPRANKS
·
24 Mar

Moleculin Biotech FY 2024 GAAP EPS $(6.32) Misses $(3.84) Estimate

Benzinga
·
24 Mar

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
24 Mar

Moleculin Biotech Inc: Initial Data Readout of Phase 3 Miracle Trial Expected in the Second Half of 2025

THOMSON REUTERS
·
24 Mar

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
22 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

GlobeNewswire
·
19 Mar